SGMT (STOCKS)
Sagimet Biosciences Inc. Series A Common Stock
$6.470000
-0.010000 (-0.15%)
Prev close: $6.480000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- David A. Happel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $398.92M
- Employees
- 14
- P/E (TTM)
- -4.82
- P/B (TTM)
- 2.06
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $48.74M |
| Research and Development | $30.71M |
| Other Operating Expenses | $18.03M |
| Operating Income/Loss | -$48.74M |
| Income/Loss From Continuing Operations After Tax | -$43.51M |
| Income/Loss From Continuing Operations Before Tax | -$43.51M |
| Net Income/Loss | -$43.51M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$43.51M |
| Net Income/Loss Available To Common Stockholders, Basic | -$43.51M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.35 |
| Diluted Earnings Per Share | -$1.35 |
| Basic Average Shares | 32,709,884 |
| Diluted Average Shares | 32,709,884 |
| Assets | $107.76M |
| Current Assets | $107.72M |
| Cash | $104.50M |
| Other Current Assets | $3.22M |
| Noncurrent Assets | $39.00K |
| Liabilities | $5.30M |
| Current Liabilities | $5.30M |
| Accounts Payable | $2.30M |
| Wages | $579.00K |
| Other Current Liabilities | $2.42M |
| Noncurrent Liabilities | $0.00 |
| Equity | $102.46M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $102.46M |
| Liabilities And Equity | $107.76M |
| Net Cash Flow From Operating Activities | -$39.73M |
| Net Cash Flow From Operating Activities, Continuing | -$39.73M |
| Net Cash Flow From Investing Activities | $11.36M |
| Net Cash Flow From Investing Activities, Continuing | $11.36M |
| Net Cash Flow From Financing Activities | -$12.45M |
| Net Cash Flow From Financing Activities, Continuing | -$12.45M |
| Net Cash Flow | -$40.82M |
| Net Cash Flow, Continuing | -$40.82M |
| Comprehensive Income/Loss | -$43.58M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$43.58M |
| Other Comprehensive Income/Loss | -$33.19M |